Tech Company M&A Transactions
iPierian Acquisition
iPierian was bought by Bristol-Meyers Squibb. The transaction was announced on 4/29/2014. Deal value was $725 million.
Transaction Overview
Company Name
Acquired By
Announced On
4/29/2014
Transaction Type
M&A
Amount
$725,000,000
M&A Terms
Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierian's issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175 million, with the potential for additional development and regulatory milestone payments totaling $550 million, along with future royalties on net sales.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
951 Gateway Blvd
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nancy Stagliano
VP - Bus. Development
Adam Rosenthal
Browse more venture capital transactions:
Prev: 4/29/2014: Brightpearl venture capital transaction
Next: 4/30/2014: Ayla Networks venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs